<![CDATA[PharmAbcine Inc. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=30305>Sat, 25 Apr 2026 22:55:57 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[PharmAbcine Announces FDA Accepts IND Application of TTAC-0001 for the Treatment of Recurrent Glioblastoma]]>https://www.newswire.co.kr/newsRead.php?no=876535Thu, 04 Oct 2018 17:25:00 +0900<![CDATA[파멥신, 재발생 교모세포증 치료에 대한 TTAC-0001 시험용 신약 신청 건이 FDA로부터 승인 받아]]>https://www.newswire.co.kr/newsRead.php?no=876537Thu, 04 Oct 2018 17:25:00 +0900<![CDATA[PharmAbcine Announces FDA Orphan Drug Designation Granted to TTAC-0001 for Glioblastoma Multiforme]]>https://www.newswire.co.kr/newsRead.php?no=866927Mon, 02 Apr 2018 15:00:00 +0900<![CDATA[파멥신, 다형성교모세포종 치료를 위한 FDA 희귀의약품으로 TTAC-0001 지정 발표]]>https://www.newswire.co.kr/newsRead.php?no=866930Mon, 02 Apr 2018 15:00:00 +0900<![CDATA[PharmAbcine Enters Collaboration with MSD Focused on Clinical Evaluation of TTAC-0001 in Combination with KEYTRUDA® (pembrolizumab) in Recurrent Glioblastoma and Breast Cancer]]>https://www.newswire.co.kr/newsRead.php?no=864039Fri, 02 Feb 2018 18:40:00 +0900<![CDATA[파멥신, 재발성 교모세포종 및 유방암 관련 키트루다와 TTAC-0001 병용 임상 평가를 위해 MSD와 협력 계약 체결]]>https://www.newswire.co.kr/newsRead.php?no=864040Fri, 02 Feb 2018 18:40:00 +0900